探索METRNL作为脓毒症新型生物标志物:诊断潜力与分泌机制
该先导研究在脓毒症细胞与动物模型中观察到METRNL在脂多糖刺激下呈剂量和时间依赖性升高,盲肠结扎穿刺模型中血清METRNL随时间升高且与脓毒症严重程度相关,造模后1小时内即升高并早于降钙素原(PCT)和C反应蛋白(CRP)。临床纳入ICU脓毒症患者107例与非脓毒症对照95例,脓毒症患者血清METRNL显著升高。ROC分析曲线下面积METRNL为0.943[0.91-0.975]、PCT为0.955[0.929-0.981]、CRP为0.873[0.825-0.921],最佳截断值下METRNL诊断特异性91.6%高于PCT的88.4%和CRP的69.5%。内皮细胞特异性Metrnl基因敲除小鼠中脓毒症模型的大部分血清Metrnl水平降低,提示METRNL主要来源于内皮细胞。
要点
- 临床ROC分析:METRNL曲线下面积0.943[0.91-0.975],PCT为0.955[0.929-0.981],CRP为0.873[0.825-0.921],METRNL诊断能力与PCT相当。
- 最佳截断值下诊断特异性:METRNL 91.6%高于PCT 88.4%和CRP 69.5%。
- 动物模型中血清METRNL在造模后1小时内升高,早于PCT和CRP。
- 脓毒症时METRNL主要来源于内皮细胞,内皮细胞特异性Metrnl基因敲除使脓毒症小鼠大部分血清Metrnl水平降低。
- TLR4-ERK信号通过经典内质网-高尔基体途径介导脂多糖刺激下METRNL的快速分泌。
适用人群与场景
- ICU脓毒症患者107例与非脓毒症对照95例的血清样本
- 脂多糖诱导的脓毒症细胞和小鼠模型,以及盲肠结扎穿刺小鼠模型
研究设计与关键结果
- 研究类型为先导研究,纳入ICU脓毒症患者107例与非脓毒症对照95例,并以细胞和动物模型探索机制。
- 脂多糖诱导的细胞和小鼠脓毒症模型中METRNL水平呈剂量和时间依赖性显著升高;盲肠结扎穿刺小鼠模型中血清METRNL随时间升高并与脓毒症严重程度相关。
- 动物中血清METRNL在造模后1小时内升高,早于PCT和CRP。
- 临床上脓毒症患者血清METRNL水平显著高于非脓毒症对照。
- ROC分析曲线下面积[95%置信区间]:METRNL 0.943[0.91-0.975],PCT 0.955[0.929-0.981],CRP 0.873[0.825-0.921]。
- 最佳截断值下诊断特异性:METRNL 91.6%,PCT 88.4%,CRP 69.5%。
- 内皮细胞特异性Metrnl基因敲除小鼠中,脓毒症模型的大部分血清Metrnl水平降低。
- 化学抑制剂或RNA干扰抑制内质网-高尔基体途径后,脓毒症细胞模型上清液METRNL水平较对照组显著降低;Toll样受体4(TLR4)和ERK抑制剂得到类似结果。
证据类型、等级与局限
- 证据类型:先导研究,包含临床病例对照诊断准确性分析与细胞、动物机制实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为METRNL是脓毒症的新型潜在生物标志物,诊断能力与PCT相当。
- 作者认为血清METRNL在脓毒症早期快速升高,机制上主要来源于内皮细胞,TLR4-ERK信号通过经典内质网-高尔基体途径介导脂多糖刺激下的快速分泌。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis is a life-threatening condition with a high mortality rate in intensive care unit (ICU). However, rapid and accurate diagnostic criteria are still lacking. This pilot study explored the role of METRNL as a novel biomarker for sepsis by focusing on its diagnostic potential and rapid secretion mechanism.
METHODS: METRNL levels were measured in cell and animal models of sepsis. Serum samples from 107 sepsis patients and 95 non-septic controls in ICU were collected. Diagnostic performance of METRNL, Procalcitonin (PCT) and C-reactive protein (CRP) were assessed using ROC analysis. Endothelial cell-specific Metrnl gene knockout mice (EC-Metrnl-/- mice) were used to identify the source of METRNL secretion. Chemical inhibitors and RNA interference were used to explore the secretion pathways.
RESULTS: In lipopolysaccharide (LPS)-induced cell and mouse models of sepsis, METRNL levels significantly increased in a dose- and time-dependent manner. Similarly, in the cecal ligation and puncture mouse models, serum METRNL levels were elevated over time and correlated with sepsis severity. In animals, serum METRNL increased within 1 h post-modeling, preceding PCT and CRP. Clinically, sepsis patients had significantly higher serum METRNL levels. ROC analysis showed area under the curves [95% confidence intervals] of 0.943 [0.91-0.975] for METRNL, 0.955 [0.929-0.981] for PCT and 0.873 [0.825-0.921] for CRP. At the optimal cutoff value, METRNL (91.6%) exhibited relatively greater diagnostic specificity than PCT (88.4%) and CRP (69.5%). EC-Metrnl-/- reduced majority of serum Metrnl levels in sepsis mouse models. Inhibition of the endoplasmic reticulum-Golgi (ER-Golgi) pathway through chemical inhibitors or RNA interference significantly reduced METRNL levels in the supernatant of sepsis cell models compared to control groups. Similar results were obtained with Toll-like receptor 4 (TLR4) and ERK inhibitors.
CONCLUSIONS: This pilot study demonstrates that METRNL is a novel potential biomarker for sepsis with diagnostic capability comparable to that of PCT. Serum METRNL rapidly increased during the early phase of sepsis. Mechanistically, it mainly originates from the endothelium during sepsis, and TLR4-ERK signaling mediates the rapid secretion of METRNL via the classical ER-Golgi pathway in response to LPS stimulation.
参考来源
- Xu TY, Zhao JX, Chen MY, et al. Exploring METRNL as a novel biomarker in sepsis: diagnostic potential and secretion mechanism. J Intensive Care. 2025. PMID: 40205457. doi:10.1186/s40560-025-00780-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。